Annual Scientific Report

Annual Scientific Report

Annual Scientific Report 2011 1 Index Introduction by Director and President 2 2 Executive Summary 4 2.1. Global Analysis 6 2.2. Research Structure 12 2.3. Training Report and Teaching 19 2.4. Innovation and Transfer Activities 24 2.5. Quality Assurance Activities 31 2.6. Clinical Trials 35 2.7. Platforms 53 2.8. Scientific Production 62 2.9. RETICs and CIBERs 70 2.10. Institutional Projects 72 2.11. Impact upon Clinical Practice 74 2.12. Internationalisation 76 3 Information Groups by Area 78 3.1 Neuroscience Area 80 3.2 Cardiovascular Area 112 3.3 Infectious Diseases and Immunity Area 142 3.4 Large Systems Pathology Area 168 3.5 Cancer and Human Molecular Genetics Area 200 4 3.6 Surgery, Transplantation and Health Technology Area 242 Associated Clinics 270 1

1 Introduction by Director and President Dr. Francisco García Río Director of IdiPAZ Dr. Rafael Pérez-Santamarina Feijóo Managing Director HULP Advisory Board Chairman IdiPAZ Once again, it gives us great pleasure to present the annual scientific report of the Instituto de Investigación Sanitaria del Hospital Universitario La Paz (Health Research Institute of the La Paz University Hospital, IdiPAZ). This report reflects the effort of the forty-eight consolidated and emerging research groups constituting IdiPAZ as well as their associated clinical groups. We congratulate all members for the magnificent work they performed and the results they achieved. IdiPAZ, formally constituted on the 15th of December, 2009, through the signing of the collaboration agreement between the Servicio Madrileño de Salud (Madrid Health Department), the Universidad Autónoma de Madrid (Autonomous University of Madrid), and the Fundación para la Investigación Biomédica del Hospital Universitario La Paz (Biomedical Research Foundation of the University Hospital La Paz), seeks to manage the entirety of the hospital and the hospital s member group resources for research, development and innovation. The collaboration between its members has helped create multidisciplinary teams to address joint research projects, maximise human resources and materials resources for research and promote research fundraising. The receipt of accreditation for IdiPAZ as a Healthcare Research Institute by the Ministry of Science and Innovation on April 19, 2010, represented recognition of the excellence of our research teams, placing us as a reference centre for biomedical research. 2

Annual Scientific Report 2011 Over the years we have maintained progressive growth in our scientific activity, which is structured into six research areas: neurosciences, cardiovascular diseases; infectious diseases and immunity; large system pathology; human cancer, molecular genetics and surgery, and transplants and health technology. In 2011, IdiPAZ researchers published 867 articles, achieving a global impact factor of 3810.53, which represents an IF score of 4.40 per published article. The quality of source journals also experienced a marked increase, with 45.1% of manuscripts generated in 2011 published in journals in the top 25 percent of their subject area. In 2011, the development of the training activities of IdiPAZ was maintained, with an attractive range of courses. The university involvement of most of the research groups has resulted in high participation in doctoral programmes, generating 37 doctoral theses this year. We are fully aware of the need to improve the transferability of biomedical research. The commitment of IdiPAZ research groups in this area has helped us secure 47 patents and nine registered trademarks to date, of which three have been licensed during this last period. In addition, our clinical research activity is one of the highest in Spain, and we are one of the centres with the largest number of clinical trials. More specifically, 297 new contracts for clinical trials were signed in 2011. The numerous and growing scientific contributions performed by our research groups over the years have placed IdiPAZ among the top three health research institutes with the highest scientific output in the country. We are confident that this annual scientific report of IdiPAZ will provide an excellent tool for reflection, critical analysis and development of proposals for improvement in the years to come. 3 Return to the index

2 4

2 Executive Summary Annual Scientific Report 2011 2.1. Global Analysis 2.2. Research Structure 2.3. Training Report and Teaching 2.3.1. Training Committee 2.3.2. Training courses conducted by IdiPAZ in 2011 2.3.2. IdiPAZ Thesis 2.4. Innovation and Transfer Activities 2.4.1. Innovation and Transfer Activities 2.4.2. Patents 2.4.3. Trademarks 2.5. Quality Assurance Activities 2.5.1. Quality Assurance Committee 2.5.2. Protocols and Clinical Pathways 2.6. Clinical Trials 2.7. Platforms 2.7.1. Biobank 2.7.2. UCICEC 2.7.3. Experimental Surgery Section 2.7.4. Cell Cultures 2.7.5. Automatic Sequencing Laboratory 2.7.6. Immunohistochemistry and Image Analysis Laboratory 2.7.7. Radioisotope Laboratory 2.7.8. Flow Cytometry Laboratory 2.7.9. Molecular Biology Laboratory 2.7.10. Biostatistics Section 2.8. Scientific Production 2.9. RETICs and CIBERs 2.10. Institutional Projects 2.11. Impact upon Clinical Practice 2.12. Internationalisation 5 Return to the index

2 Executive Summary 2.1. Global Analysis During 2011, IdiPAZ research groups have completed 867 publications, 708 of which correspond to original articles. Fifty-one percent of published articles belong to IdiPAZ, which is understood as those documents in which the first or last signatory or the author for correspondence is a member of the Instituto de Investigación Sanitaria del Hospital Universitario La Paz (Health Research Institute of the La Paz University Hospital). NUMBER OF PUBLICATIONS NUMBER IF Mean IF Publications 867 3810.53 4.40 Owned Publications 438 1323.66 3.02 Un-owned Publications 429 2486.87 5.80 Originals 708 3198.84 4.52 Owned Originals 319 905.08 2.84 Un-owned Originals 389 2293.76 5.90 The progression of the overall Impact Factor (IF) of all IdiPAZ publications in recent years is shown in the following figure. In 2011, the scientific output of IdiPAZ reached an IF of 3810.53. We can observe a constant progression during the first years of accreditation of the institute, which represents an increase of 24.2% over 2010 and 42.9% over 2009. Impact Factor 4000 3500 4000 3000 3500 2500 3000 2000 2500 1500 2000 1000 1500500 1000 0 500 2008 2009 2010 2011 0 The mean IF achieved by each manuscript 2008 was 4.40 2009 in 2011, reflecting 2010 a progressive 2011 increase in the average impact of documents generated by IdiPAZ researchers, representing an increase of 11% over the previous year. Mean IF 5 5 4 4 3 3 2 2 1 1 0 0 2008 2009 2010 2011 2008 2009 2010 2011 6 100 90

4000 3500 3000 2500 2000 1500 1000 500 0 Annual Scientific Report 2011 2008 2009 2010 2011 The quality of the journals in which the articles were published has also experienced a marked improvement. In 2008, 11.8% of IdiPAZ articles were published in journals that were in the top ten percent of their subject area. In 2011, the percentage of IdiPAZ articles published in the top ten percent was 23.3%. Moreover, 45.1% of the articles were published in journals in the top 25 percent (first quartile) of their field. 5 4 DISTRIBUTION BY DECILE AND QUARTILE 3 2 Originals 1 172 333 154 90 86 45 0 The evolution of the distribution by 2008 quartile of the 2009 articles published 2010in the last four 2011 years showed a remarkable increase in the relevance of the source journals. As shown in the following figure, the percentage of articles published in first quartile journals went from 8.9% in 2008 to 45.1% in 2011. Moreover, the percentage of publications in last quartile or unindexed journals continued to undergo a marked decline. Distribution by quartile 2008-2011 100 90 1 st DECILE 1 st QUARTILE 2 nd QUARTILE 3 rd QUARTILE 4 th QUARTILE NOT INDEXED Publications 202 391 198 119 102 57 80 70 60 50 40 30 Quartile 1 (%) Quartile 2 (%) Quartile 3 (%) Quartile 4 (%) Non indexed (%) 20 10 0 2008 2009 2010 2011 If we only consider originals published by IdiPAZ researchers, we also observe a marked increase in IF and in mean IF. The IF of the originals exceeded the 3000-point threshold for the first time, reaching 3198.84, which represents a 23.1% increase over the previous year. Moreover, 24.3% of the originals published in 2011 were in journals in the top ten percent of their subject area, and 47.0% in first quartile journals. IF for Original Papers 3500 3500 3000 3000 2500 2500 2000 2000 1500 1500 1000 1000 500 500 0 0 2008 2008 2009 2009 2010 2010 2011 2011 Mean IF for Original Papers 5 5 4 4 3 3 2 2 1 1 0 0 2008 2008 2009 2009 2010 2010 2011 2011 3,5 3,5 7 3 3

1000 2 500 0 2008 2009 2010 2011 5 Executive Summary Global Analysis 2.1. 4 3 The citation analysis shows 2 that by the time this report was written, articles published in 2011 had received 2008 citations, which represents a citation index of 1.87 and an H index of 16. For originals, the citation index is 2.08. 1 As shown in the following figure, the difference between the citation index reached by the originals and that achieved by the totality of the published manuscripts has increased over the 0 years. 3500 Citation index 3000 3,5 2500 2000 3 1500 2,5 1000 2 500 2008 2009 2010 2011 1,50 1 0,5 5 0 4 2008 2009 2010 2011 Total Original papers 2008 2009 2010 2011 3 50 The degree of integration of IdiPAZ researchers in national and international scientific networks is evidenced 2 by the high number of articles published in collaboration, which accounts for more than 75% of the total 401 documents published. For originals, 55.9% were completed in collaboration with other national institutions, and 44.1% in collaboration 0 with authors from international institutions. Compared to last year, the percentage of 30 2008 2009 2010 2011 international collaboration in originals has increased by 15%. % 20 3,5 Total 10 Collaborations 3 Original papers Publications 76.59% 57.08% 42.92% 0 2,5 2008 2009 2010 2011 Un-owned Publications 2 100.00% 50.58% 49.42% 0,5 International Collaboration 0 50 Collaborative Publications 2008 2009 2010 National Original papers 2011 International Collaborations Owned Publications 53.65% 68.94% 31.06% Originals 1,5 82.06% 55.94% 44.06% Owned Originals 1 60.19% 67.71% 32.29% Un-owned Originals 100.00% Total 50.13% 49.87% 40 % 30 20 10 0 Total 2008 2009 2010 Original papers 2011 Collaboration among IdiPAZ research groups is also reflected by the percentage of intramural collaborations, which reached 13.0% in 2011 for the totality of manuscripts and 13.1% for originals. 8

Annual Scientific Report 2011 The upward trend in scientific activity carried out by the 48 research groups of IdiPAZ is also reinforced by the analysis of IdiPAZ originals. For working purposes, IdiPAZ originals are those articles where the first or last signatory is a member of the institute. In 2011, 319 original IdiPAZ articles were published, accumulating an impact factor of 905.08. The growth rates achieved in previous years has been maintained, both in the relative number of published originals and in the overall impact factor. Number of articles 350 300 250 200 Number of articles 150 100 350 300 250 200 150 100 50 50 1,000 1,000 900 900 800 800 700 700 600 600 500 500 400 400 Impact factor Impact factor 300 300 200 200 100 100 0 0 2005 2005 2006 2006 2007 2007 2008 2009 2010 2011 0 0 Number of Original Papers in the First Quartile 120 120 100 80 60 40 100 80 60 40 20 0 20 0 2005 2006 2007 2008 2009 2010 2011 2005 2006 2007 2008 2009 2010 2011 Likewise, there was a clear increase in the quality of journals in which IdiPAZ originals were published. In 2011, 103 IdiPAZ original articles were published in journals in the top 25 percent of their subject area, showing a consolidation of the quality of scientific production. 9 Return to the index

2 Executive Summary Global Analysis 2.1. Analysis by Research Area The following summarises the main indicators of scientific activity performed by the six areas that make up IdiPAZ. Number of documents 200 150 100 143 123 195 164 131 104 191 144 134 114 110 93 50 0 7 6 7 Area 1 12 14 5 4 13 10 Area 2 Area 3 Area 4 Area 5 Area 6 Total Original Editorial Letter Review 17 15 15 7 4 9 3 8 6 Distribution of the manuscripts Decil 1 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Non indexed Area 1 17.48 41.26 23.08 12.59 17.48 5.59 Area 2 32.82 51.28 32.31 11.79 0.00 4.62 Area 3 29.01 54.20 19.85 17.56 6.11 2.29 6% Neuroscience Area 4 19.90 41.88 14% 13.09 19.37 16.23 9.42 Area 5 16% 20.90 50.00 20.15 10.45 Cardiovascular 16.42 2.99 Area 6 14.55 33.64 20.00 13.64 21.82 10.91 Infectious diseases and immunity Impact factor and citation index Pathology of large systems Impact factor Mean IF Number of Citation 15% Total Originals Total Original Cites Index 34% Cancer and human molecular Area 1 552.02 489.19 3.86 3.98 214 1.50 genetics Area 2 1387.17 1234.51 7.11 7.53 571 2.93 Area 3 590.13 482.11 4.50 4.64 Surgery, 284transplantation 2.17 and Area 4 604.4615% 463.54 3.16 3.22 health 259 technology 1.36 Area 5 642.12 529.44 4.79 4.64 242 1.81 Area 6 259.27 209.19 2.36 2.25 111 1.01 10

0 7 6 7 Area 1 12 14 5 4 13 10 Annual Scientific Report 2011 Area 2 Area 3 Area 4 Area 5 Area 6 Total Original Editorial Letter Review 17 15 15 7 4 9 3 8 6 IF distibution by area 16% 6% Neuroscience 14% Cardiovascular Infectious diseases and immunity Pathology of large systems 15% 34% Cancer and human molecular genetics 15% Surgery, transplantation and health technology Collaboration analysis Papers in Collaboration, % National Collaboration, % International Collaboration, % Area 1 67.83 69.07 30.93 Area 2 81.03 31.01 68.99 Area 3 81.68 64.49 35.51 Area 4 75.39 69.44 30.56 Area 5 81.34 55.96 44.04 Area 6 64.55 67.61 32.39 Other activities Doctoral Theses Clinical Trials Area 1 6 38 Area 2 3 42 Area 3 1 63 Area 4 10 32 Area 5 10 52 Area 6 1 9 11 Return to the index

2 Executive Summary Ṛesearch Structure 2.2 2.2. Research Structure GOVERNING COUNCIL Chairman: Patricia Flores Cerdán. Deputy Minister of Health Care CAM Deputy Chairman: José María Sanz Martínez. Chancellor of UAM Members: Rafael Pérez-Santamarina Feijóo. Chairman of the Board of FIBHULP Antonio Romero Plasencia. FIBHULP Patron Juan Antonio Vargas Núñez. UAM Representative Rodolfo Álvarez-Sala Walther. FIBHULP Patron Francisco García Río. Scientific Director IdiPAZ Ana Frank García. FIBHULP Patron Antonio Gil Aguado. FIBHULP Patron Exuperio Díez Tejedor. FIBHULP Patron Juan Antonio Tovar Larrucea. FIBHULP Patron Francisco Arnalich Fernández. UAM Representative Fernando Rodríguez Artalejo. UAM Representative Amparo Cano García. UAM Representative Damián García Olmo. FIBHULP Patron Pablo Lapunzina Badía. FIBHULP Patron Secretary: Ana Coloma Zapatero. Director of FIBHULP EXECUTIVE COMMITTEE Chairman: Rafael Pérez-Santamarina Feijóo. Chairman of the Board of FIBHULP Members: Juan Antonio Vargas Núñez. Dean of UAM Medical School Francisco García Río. Scientific Director IdiPAZ Ana Coloma Zapatero. Director of FIBHULP José Ramón Arribas López. HULP Representative Francisco Arnalich Fernández. UAM Representative Secretary: Ana Coloma Zapatero. Director of FIBHULP SCIENTIFIC DIRECTOR Francisco García Río EXTERNAL SCIENTIFIC COMMITTEE Juan Tamargo Menéndez. Institute of Pharmacology and Toxicology CSIC-UCM. Madrid Alvar Agustí García-Navarro. IDIBAPS. Barcelona Joaquín Arribas López. Vall d Hebron Hospital. Barcelona Lina Badimón Maestre. ICCC. Barcelona Carlos Belmonte Martínez. Institute of Neurosciences. Alicante José Castillo Sánchez. C. H. University of Santiago de Compostela Isabel Fabregat Romero. IDIBELL. Barcelona Carmen Maroto Vela. University of Granada María Teresa Miras Portugal. Complutense University. Madrid Santiago Moreno Guillén. Ramón y Cajal Hospital. Madrid RESEARCH COMMITTEE Chairman: Damián García Olmo Secretary: Alejandro Balsa Criado Members: Isabel de Andrés de la Calle Francisco Arnalich Fernández Amparo Cano García Javier de Castro Carpeño Ana Frank García Juan García Puig 12

Annual Scientific Report 2011 José Antonio Rodríguez Montes David Hardisson Hernáez Pablo Lapunzina Badía José Luis López-Sendón Hentschel Leopoldo Martínez Martínez Jesús Mingorance Cruz Mercedes Salaices Sánchez Rafael Selgas Gutiérrez Fernando Rodríguez Artalejo CLINICAL RESEARCH ETHICS COMMITTEE Chairman: Antonio Gil Aguado Deputy Chairman: Jesús Frías Iniesta Secretary: Rosario Madero Jarabo Representative from the Research Committee: Alejandro Balsa Criado Members: Mario Arancón Monge Javier Arpa Gutiérrez Manuel Jiménez Lendínez Carlos Hernández Gil Jaime Fernández Bujarrabal Jaime Feliu Battle Antonio Buño Soto Almudena Castro Conde Elena García Higuera Fernando Cabañas González Luis Asensio Prianes José Ramón Paño Pardo Ángel Robles Marhuenda Elena Villamañán Bueno Rafael del Río Villegas Ramón Usandizaga Elío Filomena Trocoli González Filiberto Chuliá Fernández Member from outside the institution: Juan Antonio Sánchez Moreno Technical Secretary: Paz Lavilla Uriol Emma Fernández de Uzquiano Sol de Gracia García ANIMAL WELFARE ETHICS COMMITTEE Carmen Fernández Criado Fernando Carceller Benito Luis Álvarez García Carlota Largo Aramburu QUALITY ASSURANCE COMMITTEE Coordinator: Alberto Martín Vega Members: Blanca Fuentes Gimeno José Jonay Ojeda Feo Ángel Otero Puime Margarita Rodrigo Angulo TRAINING COMMITTEE Coordinator: Ana Isabel de Cos Blanco Members: Gema Moreno Bueno Bárbara Martínez de Miguel TECHNICAL SECRETARY María Luisa Tejedor Botello Mercedes Ruiz Balibrea DOCUMENTATION SERVICE Raúl Román Cañizares FOUNDATION FOR BIOMEDICAL RESEARCH OF LA PAZ UNIVERSITY HOSPITAL Director: Ana Coloma Zapatero Public and European Projects Manager: Ana Herrera Puerta Private Projects Manager: Francisco Gil Gadea Clinical Trial Manager: Clara Segarra Lorente Public Projects Manager: Sara Moral Álamo Institutional Projects Manager: José Luis Narro Villanueva Head of Legal Department: Sara Fernández Morata Accountants: Laura López Revuelta Mónica García López Researcher Reception and Attention: Silvia Arce Santamaría 13

2 Executive Summary Ṛesearch Structure 2.2 RESEARCH AREAS Neuroscience Area Coordinator: Exuperio Díez Tejedor GROUP NAME DIRECTOR 01 Psychiatry and Mental Health Beatriz Rodríguez Vega 02 Neurology and Cerebrovascular Diseases Exuperio Díez Tejedor 03 Neurobiological Basis of Sleep and Sensory Processing Isabel de Andrés de la Calle 04 Neuroprotective Strategies in Neurodegenerative Antonio Cuadrado Pastor Diseases 05 Cellular Proteostasis and Conformational Diseases José González Castaño 06 Structure, Neurochemistry and Plasticity of Neural Francisco Clascá Cabré Circuits of the Cerebral Cortex and Thalamus 07 Inflammatory Response Neurobiology Francisco Arnalich Fernández 30 Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies Cecilio Giménez Martín Cardiovacular Area Coordinator: José Luis López-Sendón Hentschel GROUP NAME DIRECTOR 08 Research on Invasive Clinical Cardiology - ICCI-Paz José Luis López-Sendón Hentschel 09 Clinical Epidemiology and Cardiometabolic Disease Rafael Gabriel Sánchez Prevention 10 Cardiovascular Epidemiology and Nutrition Fernando Rodríguez Artalejo 11 Metabolic-Vascular Unit Juan García Puig 13 Sex Hormones and Vascular Function Mercedes Ferrer Parra 14 Coagulopathies and Alterations of Haemostasis Víctor Jiménez Yuste 15 Vascular Physiology and Pharmacology Mercedes Salaices Sánchez Infectious Diseases and Inmunity Area Coordinator: José Ramón Arribas López GROUP NAME DIRECTOR 16 AIDS and Infectious Diseases José Ramón Arribas López 18 Molecular Microbiology Jesús Mingorance Cruz 19 Immuno-Rheumatology María Eugenia Miranda Carús 20 Innate Immune Response Eduardo López Collazo 21 Diagnosis and Treatment of Diseases Associated with Margarita López Trascasa Abnormalities of the Complement System 22 Lymphocyte Pathophysiology in Immunodeficiencies Eduardo López Granados 14

Annual Scientific Report 2011 Large System Pathology Area Coordinator: Francisco García Río GROUP NAME DIRECTOR 23 Respiratory Diseases Francisco García Río 24 Regulation of Gene Expression and by Hypoxia Luis del Peso Ovalle 25 Nephrology Rafael Selgas Gutiérrez 26 Neonatology José Quero Jiménez 27 Aging and Fragility in the Elderly Ángel Otero Puime 28 Molecular Hepatology Luis Álvarez García 44 Diagnosis and Treatment of Allergic Diseases Santiago Quirce Gancedo 47 Ophthalmology Félix Armadá Maresca 48 Gynecology and Obstetrics Ignacio Zapardiel Gutiérrez 49 Emergency Manuel Quintana Díaz Cancer and Human Molecular Genetics Area Coordinator: Jaime Feliu Batlle GROUP NAME DIRECTOR 29 INGEMM - Institute of Medical and Molecular Genetics Pablo Lapunzina Badía 31 Molecular Genetics of Dystroglycanopathies Jesús Cruces Pinto 32 Translational Oncology Jaime Feliu Batlle 33 Experimental Therapies and Biomarkers in Cancer Mª Inmaculada Ibáñez de Cáceres 34 Oto-Neurosurgery Research Luis Lassaletta Atienza 35 Anatomopathology. Breast and Gynaecological Cancer David Hardisson Hernáez 36 Mechanisms of Tumour Progression Amparo Cano García 37 Animal and Cell Models for Detection and Carmela Calés Bourdet Characterisation of Leukemic Stem Cells 45 Research and Diagnosis of Inherited Metabolic Diseases Magdalena Ugarte Pérez Surgery, Transplant and Health Technologies Area Coordinator: Juan Antonio Tovar Larrucea GROUP NAME DIRECTOR 38 Congenital Malformation Surgery Juan Antonio Tovar Larrucea 39 Experimental Surgery Juan José Vázquez Estévez 40 Bone Pathophysiology and Biomaterials Nuria Vilaboa Díaz 41 Cell Therapy And Gene Metastasis Damián García Olmo 42 Cellular Engineering María Paz de Miguel González 43 Clinical Pharmacology Jesús Frías Iniesta 12 Research in Nutrition and Functional Foods - NUTRINVEST Carmen Gómez-Candela 46 Osteoarticular Surgery Research - GICOA Enrique Gómez Barrena 15

2 Executive Summary Research Structure 2.2. PUBLIC RESEARCH CONTRACTS MIGUEL SERVET RESEARCHER CONTRACT (Carlos III Health Institute) Nora Viviana Butta Coll. Group 14. Coagulopathies and Alterations of Haemostasis María Inmaculada Ibáñez de Cáceres. Group 33. Experimental Therapies and Biomarkers in Cancer Laura Saldaña Quero. Group 40. Bone Pathophysiology and Biomaterials Fernando de Miguel Pedrero. Group 41. Cell Therapy and Gene Metastasis María Fernández Velasco. Group 20. Innate Immune Response MIGUEL SERVET RESEARCHER STABILISATION CONTRACTS (I2) (Carlos III Health Institute) Ángel Campos Barros. Group 29. INGEMM - Institute of Medical and Molecular Genetics Eduardo López Collazo. Group 20. Innate Immune Response Juan Antonio Rey Herranz. Group 34. Oto- Neurosurgery Research Teresa Bellón Heredia. Group 44. Diagnosis and Treatment of Allergic Diseases Luis Álvarez García. Group 28. Molecular Hepatology María Rosa Torres Jiménez. Group 11. Metabolic-Vascular Unit Nuria Vilaboa Díaz. Group 40. Bone Pathophysiology and Biomaterials Pilar Sánchez-Corral Gómez. Group 21. Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System María Paz de Miguel González. Group 42. Cellular Engineering Juan Ángel Fresno Vara. Group 32. Translational Oncology MIGUEL SERVET RESEARCHER STABILISATION CONTRACTS (I3) (Carlos III Health Institute) Karen Elise Heith. Group 29. INGEMM - Institute of Medical and Molecular Genetics Jesús Mingorance Cruz. Group 18. Molecular Microbiology TECHNICAL SUPPORT CONTRACTS (Carlos III Health Institute) Alba Boré Medina. Group 40. Bone Pathophysiology and Biomaterials Esther Díaz López. Group 32. Translational Oncology Fátima Domínguez Timón. Group 42. Cellular Engineering Víctor Manuel Toledano Real. Group 20. Innate Immune Response Mónica Barriuso Iglesias. Biobank RIO HORTEGA POSTGRADUATE CONTRACTS (Carlos III Health Insitute) María Elena González García. Group 25. Nephrology Irina Diana Bobolea. Group 44. Diagnosis and Treatment of Allergic Diseases Ignacio Pérez Valero. Group 16. AIDS and Infectious Diseases Miriam Estebánez Muñoz. Group 16. AIDS and Infectious Diseases Krista Lundelin. Group 11. Metabolic- Vascular Unit Francisco Xavier Zamora Vargas. Group 16. AIDS and Infectious Diseases TECHNICAL SUPPORT STABILISATION CONTRACTS (Carlos III Health Institute) Francisco Gayá Moreno. Group 16. AIDS and Infectious Diseases María Teresa Vallejo Cremades. Group 38. Congenital Malformation Surgery SARA BORREL POSTDOCTORAL CONTRACTS (Carlos III Health Institute) Marta Mendiola Sabio. Group 35. Anatomopathology. Breast and Gynaecological Cancer Ana Belén Sanz Bartolomé. Group 25. Nephrology Francisco Martín Saavedra. Group 40. Bone Pathophysiology and Biomaterials María Dolores Sánchez Niño. Group 25. Nephrology 16

Annual Scientific Report 2011 INTENSIFICATION CONTRACTS (Carlos III Health Institute) José Ramón Arribas López. Group 16. AIDS and Infectious Diseases Blanca Fuentes Gimeno. Group 2. Neurology and Cerebrovascular Diseases Francisco García Río. Group 23. Respiratory Diseases Margarita López Trascasa. Group 21. Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System PREDOCTORAL FELLOWSHIP (Carlos III Health Institute) Sergio Castrejón Castrejón. Group 8. Investigación en Cardiología Clínica e Invasiva ICCI-IdiPAZ Joaquín Poza Cordón. Group 41. Cell Therapy And Gene Metastasis Alicia González Baeza. Group 16. AIDS and Infectious Diseases María Victoria Heredia Soto. Group35. Anatomopathology. Breast and Gynaecological Cancer JUAN DE LA CIERVA CONTRACTS (Ministry of Economy and Competitiveness) María Siliceo Aznar. Group 20. Innate Immune Response RAMÓN Y CAJAL CONTRACTS (Ministry of Economy and Competitiveness) Rebeca Pérez de Diego. Group 22. Lymphocyte Pathophysiology in Immunodeficiencies FPI CONTRACTS (Ministry of Economy and Competitiveness) María Luisa de Frías Sánchez. Group 41. Cell Therapy and Gene Metastasis Verónica Barca Tierno. Group 29. INGEMM - Institute of Medical and Molecular Genetics Teresa Jurado Camino. Group 20. Innate Immune Response PTA CONTRACTS (Ministry of Economy and Competitiveness) Gema Vallés Pérez. Group 40. Bone Pathophysiology and Biomaterials PREDOCTORAL FELLOWSHIP (Ministry of Economy and Competitiveness) Lara Crespo García. Group 40. Bone Pathophysiology and Biomaterials FPI CONTRACTS (Autonomous Community of Madrid) Virginia Cebrián Hernando. Group 40. Bone Pathophysiology and Biomaterials PREDOCTORAL FELLOWSHIP (Autonomous Community of Basque Country) Alfonso Hisado Oliva. Group 29. INGEMM - Institute of Medical and Molecular Genetics 17

2 Executive Summary Ṛesearch Structure 2.2 2011 DATA: HUMAN RESOURCES PROGRAMME ORGANISATION No. OF CONTRACTS Established I3 Autonomous Community of Madrid 2 Estabilished I2 Carlos III Health Institute/ALE 10 Technical Support Stabilisation Autonomous Community of Madrid 2 Contracts TOTAL ESTABLISHED 14 PTA Contracts Ministry of Economy and Competitiveness 1 Juan de la Cierva Contracts Ministry of Economy and Competitiveness 1 Ramón y Cajal Contracts Ministry of Economy and Competitiveness 1 FPI Contracts Ministry of Economy and Competitiveness 3 Technical Support Contracts (FIS) CA Carlos III Health Institute 5 FPI Contracts Autonomous Community of Madrid 1 Sara Borrell Contracts PD Carlos III Health Institute 4 Río Hortega Contracts CM Carlos III Health Institute 6 Miguel Servet Contracts CP Carlos III Health Institute 5 Intensification Contracts Carlos III Health Institute 4 TOTAL PROGRAMMWES 31 Predoctoral Fellowship Carlos III Health Institute 4 Predoctoral Fellowship Autonomous Community of Basque Country 1 Predoctoral Fellowship Ministry of Economy and Competitiveness 1 TOTAL FELLOWS 6 TOTAL ESTABLISHED + PROGRAMMES + FELLOWS 51 CAIBER CAIBER 3 INGEMM Revitalization Actions (ISCIII) 2 FIS Projects Carlos III Health Institute 2 Technology Assessment Carlos III Health Institute 1 NETWORKS Themes Carlos III Health Institute 21 SAF/MAT Ministry of Economy and Competitiveness 7 No Comercial EECC Ministerio de Sanidad y Política social 5 Biobank Carlos III Health Institute 2 Comercial EECC EECC Promoters 1 Private Projects Pharmaceutical Industry 53 In-house Projects FIBHULP 11 Comercial EECC Carlos III Health Institute 1 TOTAL EMPLOYEES DEPENDET ON P.I. 109 Private Projects Pharmaceutical Industry 22 TOTAL FELLOWS DEPENDET ON P.I. 22 TOTAL STAFF DEPENDENT ON P.I. 131 Technical Unit Staff FIBHULP 11 TOTAL TECHNICAL UNIT EMPLOYYES 11 TOTAL TECHNICAL UNIT 11 TOTAL 193 18 Return to the index

Annual Scientific Report 2011 2.3. Training Report and Teaching 2.3.1. Training Committee The fundamental objective of the IdiPAZ training plan is to increase understanding in areas of interest for its researchers, offering not only activities conducted by HULP (Continuing Education) and by UAM (Postgraduate) but also the Institute s own courses, which are pre-selected according to the established needs of the members of IdiPAZ. Every year, the training committee conducts a survey to determine the needs of the Institute s members, which allows analysis of those areas of interest that require greater training and specialisation on the part of the researchers. Each of its own courses has a coordinator who works for IdiPAZ and who manages the accreditation of the course through the Agencia Laín Entralgo (The Lain Entralgo Agency, CAM). It is important to note that the Training Committee encourages the participation of IdiPAZ personnel as coordinators of their own courses, always under the aegis of the Committee itself and the department of continuing education at HULP. The editing of courses belonging to IdiPAZ is in response to the detection of training needs not covered by the IdiPAZ institutions and is the result of communication with Area Coordinators and Group Directors, as well as the analysis of the Needs Detection Survey analysis sent to members of the Institute. Support Services and teaching structures of the Institute will respond to this demand, which may also originate from external teaching organisations. It should be noted that the design of this specific training, which is managed by the IdiPAZ Training Committee, is targeted to healthcare professionals who conduct research and to research professionals. We should also point out that throughout the last two years there has been a marked growth in the participation of IdiPAZ personnel in the Institute s own courses, which has resulted in higher quality training opportunities. Composition Coordinator: Ana Isabel de Cos Blanco E-mail: formacion@idipaz.es Members: Gema Moreno Bueno Bárbara Martínez de Miguel 19